These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 12389116)

  • 1. Drug resistance in prostate cancer cell lines is influenced by androgen dependence and p53 status.
    Serafin AM; Akudugu JM; Bohm L
    Urol Res; 2002 Oct; 30(5):289-94. PubMed ID: 12389116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of p53 and bcl-2 on chemosensitivity in benign and malignant prostatic cell lines.
    Serafin AM; Bohm L
    Urol Oncol; 2005; 23(2):123-9. PubMed ID: 15869997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
    Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of microtubule inhibitors-taxol, vinblastine and estramustine on the growth and p53 gene expression in the hormone independent human prostatic JCA-1 cells.
    Darby E; An S; Ng C; Hsieh TC; Mallouh C; Wu JM
    Anticancer Res; 1996; 16(6B):3647-52. PubMed ID: 9042236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma.
    Arah IN; Dixon SC; Horti J; Figg WD
    Neoplasma; 1999; 46(2):117-23. PubMed ID: 10466436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
    Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC
    Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells.
    Drew L; Fine RL; Do TN; Douglas GP; Petrylak DP
    Clin Cancer Res; 2002 Dec; 8(12):3922-32. PubMed ID: 12473608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen and taxol cause cell type-specific alterations of centrosome and DNA organization in androgen-responsive LNCaP and androgen-independent DU145 prostate cancer cells.
    Schatten H; Ripple M; Balczon R; Weindruch R; Chakrabarti A; Taylor M; Hueser CN
    J Cell Biochem; 2000 Jan; 76(3):463-77. PubMed ID: 10649443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ciprofloxacin inhibits cell growth and synergises the effect of etoposide in hormone resistant prostate cancer cells.
    El-Rayes BF; Grignon R; Aslam N; Aranha O; Sarkar FH
    Int J Oncol; 2002 Jul; 21(1):207-11. PubMed ID: 12063570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer.
    Yu S; Wang X; Ng CF; Chen S; Chan FL
    Cancer Res; 2007 May; 67(10):4904-14. PubMed ID: 17510420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor activity is inhibited in response to genotoxic agents in a p53-independent manner.
    Mantoni TS; Reid G; Garrett MD
    Oncogene; 2006 May; 25(22):3139-49. PubMed ID: 16434973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of prostate-specific antigen gene expression by an LH-RH analogue in human prostatic cells.
    Sica G; Zelano G; Settesoldi D; Iacopino F
    Anticancer Res; 2003; 23(2B):1283-7. PubMed ID: 12820384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
    Zhang M; Latham DE; Delaney MA; Chakravarti A
    Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased sensitivity of a metastatic model of prostate cancer to a novel tetravalent platinum analog.
    Mujoo K; Watanabe M; Khokhar AR; Siddik ZH
    Prostate; 2005 Jan; 62(1):91-100. PubMed ID: 15389812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells.
    Bruckheimer EM; Spurgers K; Weigel NL; Logothetis C; McDonnell TJ
    J Urol; 2003 Apr; 169(4):1553-7. PubMed ID: 12629413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone morphogenetic protein-2 induces hypophosphorylation of Rb protein and repression of E2F in androgen-treated LNCaP human prostate cancer cells.
    Tomari K; Kumagai T; Shimizu T; Takeda K
    Int J Mol Med; 2005 Feb; 15(2):253-8. PubMed ID: 15647840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
    Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
    Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
    Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
    Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptotic signaling in bufalin- and cinobufagin-treated androgen-dependent and -independent human prostate cancer cells.
    Yu CH; Kan SF; Pu HF; Jea Chien E; Wang PS
    Cancer Sci; 2008 Dec; 99(12):2467-76. PubMed ID: 19037992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.